Comparing two blood tests to guide iron treatment in adults on dialysis
Compares two blood tests to decide iron doses in adults on hemodialysis with anemia.
Plain-language title generated from the registry record
Registry title: Comparing Reticulocyte Hemoglobin and Transferrin Saturation to Guide Iron Treatment in People on Dialysis
Key facts
- Where
- Pathumwan, ThailandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06906835, who can take part
Where in Thailand
- King Chulalongkorn Memorial HospitalPathumwan, ThailandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- King Chulalongkorn Memorial Hospital
- Trial code
- NCT06906835
- Record updated
- 4 April 2025
- Original description
The goal of this clinical trial is to find out which method is better for guiding iron treatment in adult patients with end-stage kidney disease (ESKD) on hemodialysis who have anemia.Read full original descriptionShow less
Efficacy of Reticulocyte Hemoglobin Equivalent-guided Versus Transferrin Saturation-guided Iron Supplement Protocol in Hemodialysis Patients: A Cluster Randomized Controlled Trial
The goal of this clinical trial is to find out which method is better for guiding iron treatment in adult patients with end-stage kidney disease (ESKD) on hemodialysis who have anemia.
The main questions it aims to answer are:
Can using reticulocyte hemoglobin equivalent (RET-He) to guide intravenous (IV) iron treatment be as effective as using transferrin saturation (TSAT)?
Does the method used to guide iron treatment affect outcomes such as death, heart problems, hospitalizations, infections, or the need for blood transfusions?
Researchers will compare RET-He-guided iron treatment with TSAT-guided iron treatment to see if RET-He works just as well and has similar or better outcomes.
Participants will:
Receive IV iron based on either RET-He or TSAT levels
Have blood tests done at the start, 3 months, and 6 months
Have their doses of iron and erythropoietin (a medication to treat anemia) adjusted based on the assigned protocol
Be monitored for clinical outcomes such as hospitalization, heart events, and infections
Inclusion: Adult (age 18-80 years); ESKD on chronic hemodialysis ≥ 6 months; EPO therapy ≥ 6 months; Hb < 13.0 g/dL in male, < 12.0 g/dL in female.
Exclusion: History of GI or external bleeding or receiving blood transfusion in past 6 months; Active infection or malignancy; Hematologic disease including thalassemia major, hemolysis, myelofibrosis or myelodysplastic disease; History of marrow suppressive or immunosuppressive medications in past 6 months; History of active heart failure and recent myocardial infarction /stroke in past 6 months; Serum ferritin > 800 ng/mL or TSAT > 40%.